OrisDX raised $4 million to support the launch of its saliva-based multiomic platform for the detection of oral cancer.
OrisDX offers a non-invasive oral rinse with 93% sensitivity and 99% specificity, according to a June 10 news release.
The company said the new funding will go toward the commercial rollout of its diagnostic platform across dental, oncology and medical channels.
